Three Lakes 12-20
Three Lakes 12-20 is a public 501(c)(3) research foundation that funds and coordinates translational research, clinical trials, and AI-driven diagnostic tools for pulmonary fibrosis and interstitial lung disease, serving patients, academic researchers, and clinicians.
- Company typePrivate
- Founded2025
- HeadquartersWashington, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Three Lakes 12-20 does
Three Lakes 12-20 (TL 12-20) is a public 501(c)(3) research foundation operating within New Venture Fund, established in 2025 to accelerate the development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). It is the successor to Three Lakes Foundation, a private foundation originally funded by a family affected by idiopathic pulmonary fibrosis, and inherits a research portfolio that has channeled more than $20M toward PF initiatives since 2020. The foundation serves three primary beneficiary groups: PF and ILD patients (an estimated 100,000+ US patients with median 3-5 year survival post-diagnosis), translational researchers facing funding gaps in the "valley of death" between discovery and clinical development, and clinicians needing better diagnostic and educational tools.
The foundation operates a portfolio of research programs rather than commercial products. Core translational assets include PF-COLLECT (a pharmaceutical-foundation consortium validating cryopreserved human precision cut lung slices), the IPF Cell Atlas (open-source single-cell RNA sequencing resource co-developed with Yale and Baylor), TLC4PF (AI and single-cell profiling consortium with Yale and Pittsburgh including the Unagi perturbation simulator), PROLIFIC (blood-based biomarker assay consortium with pharma), and the B4PF1.0/B4PF2.0 early-detection programs at Vanderbilt. Diagnostic and educational tools include Mayo Clinic's AI-based EHR screening for IPF and the TED-IPF CT prediction tool, the CHEST Bridging Specialties Toolkit, and the Ask the Expert series. The foundation also supports multiple clinical trials spanning telomere biology (Telomere Trial), repurposed therapeutics (Metformin, Zinc/Nicotinamide Riboside, EGCG), genomic-stratified care (PRECISIONS), and pragmatic antimicrobial therapy (Clean-UP IPF with Duke). Strategic academic and clinical partners include Mayo Clinic, Yale, Vanderbilt, Cedars-Sinai, Baylor, University of Pittsburgh, Weill Cornell, Duke Clinical Research Institute, the Pulmonary Fibrosis Foundation, NHLBI, and Lung Foundation Australia.
TL 12-20's revenue model is philanthropic: it accepts donations via credit card, ACH, wire, check, and stock, with administrative costs fully covered by an anonymous donor through 2026 so that 100% of new contributions flow directly to research. Distribution of "outputs" occurs through direct research grants to academic investigators, collaborative consortia with pharmaceutical companies, and educational content deployed via conferences (ATS, ICLAF, Team Telomere, FusionLung26), website/blog, email newsletter, and LinkedIn. Patient delegate stories and the Make Connor Run fundraising campaign drive community engagement and donor cultivation.
Three Lakes 12-20 firmographics
Firmographics- Name
- Three Lakes 12-20
- Legal name
- Three Lakes 12-20 Pulmonary Fibrosis Research Foundation
- Website
- https://threelakes1220.org
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Three Lakes 12-20 is a public 501(c)(3) research foundation that funds and coordinates translational research, clinical trials, and AI-driven diagnostic tools for pulmonary fibrosis and interstitial lung disease, serving patients, academic researchers, and clinicians.
- Ownership category
- akta.pro rank
Three Lakes 12-20 industry classification
Industry- Product category
- Medical Research Foundation
- NAICS
- Grantmaking Foundations (813211), Voluntary Health Organizations (813212), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Grantmaking and Giving Services (81321)
- SIC
- Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Health & Medical Research Grantmaking Foundations (BPAGAKAL)
- akta.pro secondary industries
- Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Global Health Research, Evidence & Technical Assistance Organizations (HLAJAKAN), International & Global Public Health Aid Administration (Government Donors) (HLAJALAO)
Keywords
Where Three Lakes 12-20 is headquartered
LocationHeadquarters
- HQ city
- Washington
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Three Lakes 12-20 business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Operations, Personnel, Marketing or Sales, Technology or R&D, Others
Revenue model
- Donations and Philanthropic Contributions: As a 501(c)(3) public charity operating within New Venture Fund, Three Lakes 12-20 raises funds from donors to support pulmonary fibrosis research. Administrative costs are covered through 2026 by an anonymous donor, allowing 100% of donations to be directed to research projects.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Three Lakes 12-20 product offering
Product offeringCore offering
Three Lakes 12-20 is a public research foundation that funds, coordinates, and accelerates pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. Its core offerings include the PF-COLLECT Consortium for human tissue resources, the IPF Cell Atlas open-source single-cell RNA sequencing resource, the TLC4PF and PROLIFIC AI/single-cell consortia, the B4PF1.0/B4PF2.0 early disease detection programs, multiple funded clinical trials, the CHEST Bridging Specialties diagnostic tool, and the Ask the Expert educational series. The foundation operates within New Venture Fund as a 501(c)(3) public charity and channels 100% of donations to research through 2026.
Product overview
Three Lakes 12-20 is a public research foundation (operating within the New Venture Fund) focused on accelerating development of effective therapies and translational resources for pulmonary fibrosis (PF) and interstitial lung disease (ILD). Rather than offering commercial products, the foundation operates a portfolio of research initiatives and programs: the PF-COLLECT Consortium for developing human tissue resources; the IPF Cell Atlas, PROLIFIC Consortium, and TLC4PF research initiatives using AI and single-cell profiling; B4PF1.0/B4PF2.0 for early disease research; and the Mayo Clinic diagnostic tools including AI-based screening. The foundation also funds multiple clinical trials (Telomere Trial, Zinc/NR, Metformin, EGCG, PRECISIONS, Clean-UP IPF), an Ask the Expert educational series, the CHEST Bridging Specialties diagnostic tool, and the Make Connor Run fundraising program. Administrative costs are covered through 2026 via anonymous donor, enabling 100% of donations to fund critical research projects.
Differentiator
Problem solved
Functional benefit
Brands
- PF-COLLECT: Pulmonary Fibrosis Consortium for Living Lung Excised Tissue - A consortium consisting of Pharmaceutical and Foundation Members who collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate the development of therapies for ILD and PF.
Products and services
- PF-COLLECT Consortium Pulmonary Fibrosis Consortium for Living Lung Excised Tissue (PF-COLLECT). A consortium of pharmaceutical and foundation members that collaborate to validate cryopreservation and develop human-based tissue resources and assays to accelerate development of therapies for ILD and PF. Designed for pharmaceutical researchers and academic investigators needing access to validated human precision cut lung slices (hPCLS).
- IPF Cell Atlas Collaborative open-source resource enabling researchers to explore single-cell RNA sequencing datasets from IPF tissue. Contains data from hundreds of thousands of cells from healthy and diseased lungs and enables identification of cell populations driving disease including aberrant basaloid cells, profibrotic macrophages, and expanded vascular endothelial cells.
- PROLIFIC Consortium Consortium developing well-qualified assays to measure selected blood-based protein biomarkers linked to IPF. Involves leading pharmaceutical companies and foundations focused on PF/ILD biomarker validation.
- TLC4PF (Three Lakes Consortium for Pulmonary Fibrosis) Consortium using AI and cutting-edge single-cell profiling technologies to identify potential treatments for PF and validate efficacy with human tissue-based models. Includes the Pulmonary Fibrosis Connectome workgroup at Yale and the PF Translation workgroup at University of Pittsburgh; the McGill team created the Unagi webserver for exploring cellular dynamics and simulating perturbations.
- B4PF1.0 and B4PF2.0 (Before the PF) Research programs studying subclinical or early disease in asymptomatic relatives of PF patients to understand natural progression and identify biomarkers and drug targets. B4PF1.0 uses single-cell sequencing and spatial transcriptomics on lung biopsy samples; B4PF2.0 analyzes HRCT scans using radiomic signatures for disease risk and progression prediction.
- Ask the Expert Series Forum providing access to industry professionals working towards treatment and future of pulmonary fibrosis. Monthly expert Q&A sessions with leading researchers and clinicians for patients, caregivers, and clinicians.
- CHEST Bridging Specialties Tool Multiphase educational tool designed to reduce diagnostic delays for patients with Interstitial Lung Diseases including pulmonary fibrosis. Contains ILD-specific patient questionnaire, e-learning module, and decision-making tool developed for clinicians and pulmonologists.
- Telomere Trial Phase I clinical trial assessing safety and biological effects of deoxycytidine plus thymidine to lengthen telomeres in PF patients, addressing telomere shortening linked to worse prognosis. Targets PF patients with short telomere signatures.
- Zinc and Nicotinamide Riboside Trial Decentralized, double-blind randomized controlled trial testing combination of zinc and nicotinamide riboside in patients with IPF, targeting mitochondrial function, DNA repair, and energy metabolism via NAD+. Led by Dr. Tanzira Zaman at Cedars-Sinai.
- Metformin Study Clinical trial validating whether patients with pulmonary fibrosis benefit from treatment with metformin, building on findings that patients with both PF and type 2 diabetes treated with metformin had reduced mortality and hospitalizations.
- PRECISIONS Trial First pulmonary fibrosis trial using a genomic-driven approach to identify patients most likely to respond to treatment with N-Acetylcysteine (NAC), using blood transcriptomics, proteomics, and genomics.
- Clean-UP IPF First pragmatic trial in IPF studying whether antimicrobial therapy improves hospitalization or decreases death, evaluating effectiveness in real-life settings. Coordinated with Duke Clinical Research Institute and supported by NHLBI.
- Make Connor Run Annual fundraising campaign where Connor Tully runs 1 mile for every $50 raised in June on behalf of his father, Tom Tully, a pulmonary fibrosis patient and lung transplant recipient. Funds support early detection and prevention research.
Quantifiable outcome
- Over $20M administered toward PF research initiatives since 2020
- +3 more outcomes
Companies that use Three Lakes 12-20
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Three Lakes 12-20 technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability11 records
Feature5 records
Three Lakes 12-20 partnerships and signals
Strategic signalPartnerships
17 partnerships are on record, tiered core and minor.
- Lung Foundation Australia / CRE-PFcoreGlobal collaboration between Three Lakes Foundation, Lung Foundation Australia, and Australian Centre of Research Excellence for Pulmonary Fibrosis. Focused on leveraging expertise, resources, and knowledge to accelerate diagnosis, treatment, and delivery of therapies. CRE-PF supports research, educates public, and trains researchers in PF.
- Pulmonary Fibrosis Foundation (PFF)coreThree Lakes 12-20 and PFF share common goals to improve lives of PF patients. Founders have provided support for PFF patient registry, driving awareness, and research into PF causes. Collaborated with NHLBI and PFF on 2022 stakeholder summit to identify scientific gaps and research opportunities. Results published in Pulmonary Fibrosis Stakeholder Summit workshop report.
- Wescoe FoundationminorGrant from Three Lakes Foundation to Wescoe Foundation to support their work understanding needs and interests of PF patients and families. Aligned vision to unite the PF community and accelerate research and therapies.
- PF WarriorsminorPF Warriors serves global PF/ILD patient community with tools, resources, peer-to-peer programs, and webinars. Three Lakes 12-20 is aligned with their mission to help families affected by PF.
- Mayo CliniccoreMayo Clinic collaboration mapped diagnostic journey for PF, defined impact of existing therapies, and developed AI diagnostic tools. Led by Dr. Andrew Limper, developed electronic health record screening tools and identified metformin therapy potential.
- Cedars-SinaicoreZinc and Nicotinamide Riboside trial led by Dr. Tanzira Zaman at Cedars-Sinai. Original work from Dr. Paul Noble on ZIP8/SIRT1 axis regulating alveolar progenitor cell renewal. Trial tests decentralized RCT approach for IPF treatment.
- Yale University School of MedicinecoreTLC4PF consortium collaboration with Yale led by Dr. Naftali Kaminski. Pulmonary Fibrosis Connectome workgroup uses AI and single-cell profiling to identify treatments. Led development of IPF Cell Atlas.
- University of Pittsburgh School of MedicinecoreTLC4PF consortium collaboration with University of Pittsburgh. PF Translation workgroup led by Dr. Melanie Koenigshoff focuses on advancing treatments through translational research and organoid models.
- Vanderbilt University Medical CentercoreB4PF1.0 and B4PF2.0 projects led by Dr. Jonathan Kropski studying subclinical PF in first-degree relatives. Uses single-cell sequencing, spatial transcriptomics, and radiomic signatures for early detection.
- Baylor College of MedicinecoreIPF Cell Atlas development led by Dr. Ivan O. Rosas at Baylor. Collaborative open-source resource with Yale University containing hundreds of thousands of cells from healthy and diseased lungs.
- PROLIFIC ConsortiumcoreThree Lakes 12-20 is a member of PROLIFIC Consortium developing assays to measure blood-based protein biomarkers linked to IPF. Consortium includes leading pharmaceutical companies and foundations.
- National Heart, Lung, and Blood Institute (NHLBI)coreCollaborated with NHLBI and PFF on 2022 stakeholder summit. Supported Clean-UP IPF pragmatic trial. Joint initiative to identify scientific gaps and research opportunities in PF.
- American Thoracic Society (ATS)minorFoundation attends ATS International Conference (Orlando, FL, May 2026) - world's most important gathering for pulmonary, critical care, and sleep professionals.
- International Colloquium on Lung and Airway Fibrosis (ICLAF)minorFoundation attends ICLAF (Sydney, Australia, October 2026) - biennial meeting convening to discuss cutting-edge advancements in pathogenesis, management and therapies for pulmonary fibrosis.
- Team TelomereminorFoundation attends Team Telomere Scientific Summit (Missoula, Montana, July 2026) - dynamic convening of clinicians, researchers, advocates, and community leaders exploring Telomere Biology Disorders.
- American College of Chest Physicians (CHEST)coreInitial funding provided by Three Lakes Foundation for CHEST Bridging Specialties Tool - multiphase educational initiative to reduce diagnostic delays for ILD patients.
- Duke Clinical Research InstituteminorClean-UP IPF pragmatic trial collaboration with DCRI as coordinating center for NHLBI-sponsored study on antimicrobial therapy effectiveness.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Three Lakes 12-20 competitors and assessment
Company assessmentDirect peers
- Cystic Fibrosis Foundation: A disease-specific lung research foundation that pioneered the venture philanthropy model for drug development. Highly comparable in structure and mission (single-disease lung foundation funding R&D) though at vastly greater scale.
- Pulmonary Fibrosis Foundation: The largest US nonprofit dedicated to pulmonary fibrosis, operating a patient registry, support programs, and research funding. TL 12-20 and PFF share core goals and have collaborated on the 2022 NHLBI stakeholder summit; PFF is the most direct disease-focused peer.
- PF Warriors: A global PF/ILD patient community organization offering peer-to-peer programs, resources, and webinars. Direct peer in serving the same patient community with aligned mission.
- Wescoe Foundation for Pulmonary Fibrosis: A smaller PF-focused foundation that has received grants from TL 12-20. Directly comparable as a patient-support and PF research nonprofit serving the same community.
- Team Telomere: A small nonprofit focused on Telomere Biology Disorders, a related disease area that intersects with PF. TL 12-20 attends the Team Telomere Scientific Summit, signaling collaboration; comparable as a small rare-disease foundation model.
- Lung Foundation Australia / CRE-PF: Australia's primary lung disease foundation and the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF). Direct strategic partner of TL 12-20 with mutual collaboration on global PF research, training, and education initiatives.
Broad incumbents
- American Lung Association: The largest US lung health nonprofit, with broad research, advocacy, and education programs including some PF funding. Comparable as an incumbent in lung disease research funding though with a much broader mandate.
Emerging players
- Mediar Therapeutics: An emerging biotech developing anti-fibrotic therapies, founded by Dr. Paul Yaworsky who sits on TL 12-20's advisory board. Comparable as a translational PF drug development effort that the foundation's research programs aim to feed.
- Pliant Therapeutics: Clinical-stage biotech developing integrin-based therapies for IPF and other fibrotic diseases. Comparable as a PF drug developer whose translational work overlaps with TL 12-20's mission.
Others
- National Heart, Lung, and Blood Institute (NHLBI): The US government's primary funder of PF research, and a direct collaborator on the 2022 stakeholder summit and Clean-UP IPF trial. Comparable as a co-funder of the PF research ecosystem though not a competitor for donations.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Three Lakes 12-20 social profiles
Digital presenceThree Lakes 12-20 financial estimates
Financial estimateRevenue estimate
Valuation estimate
Three Lakes 12-20 leadership team
Management profileNumber of profiles
Profiles4 records
Three Lakes 12-20 funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Three Lakes 12-20 M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Three Lakes 12-20
What does Three Lakes 12-20 do?
Three Lakes 12-20 is a public research foundation that funds, coordinates, and accelerates pulmonary fibrosis (PF) and interstitial lung disease (ILD) research. Its core offerings include the PF-COLLECT Consortium for human tissue resources, the IPF Cell Atlas open-source single-cell RNA sequencing resource, the TLC4PF and PROLIFIC AI/single-cell consortia, the B4PF1.0/B4PF2.0 early disease detection programs, multiple funded clinical trials, the CHEST Bridging Specialties diagnostic tool, and the Ask the Expert educational series. The foundation operates within New Venture Fund as a 501(c)(3) public charity and channels 100% of donations to research through 2026.
Is Three Lakes 12-20 a public or private company?
Three Lakes 12-20 is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Three Lakes 12-20 founded?
Three Lakes 12-20 was founded in 2025. It employs 1 to 10 people.
Where is Three Lakes 12-20 based?
Three Lakes 12-20 is headquartered in Washington, United States, in the North America region.
How does Three Lakes 12-20 make money?
One revenue line is on record: donations and Philanthropic Contributions.
Who are Three Lakes 12-20's main competitors?
Direct peers on record are Cystic Fibrosis Foundation, Pulmonary Fibrosis Foundation, PF Warriors, Wescoe Foundation for Pulmonary Fibrosis, Team Telomere and Lung Foundation Australia / CRE-PF. American Lung Association is listed as a broad incumbent. Emerging players are Mediar Therapeutics and Pliant Therapeutics. National Heart, Lung, and Blood Institute (NHLBI) is listed as an others.
Does Three Lakes 12-20 have an API?
No public API is recorded for Three Lakes 12-20.
What industry is Three Lakes 12-20 in?
Three Lakes 12-20's product category is Medical Research Foundation. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS). Its NAICS code is 813211 and its SIC code is 8731.